References
- Dreyling M, Weigert O, Hiddemann W. Current treatment standards and future strategies in mantle cell lymphoma. Ann Oncol 2008; 19(Suppl 4)iv41–iv44
- Tiemann M, Schrader C, Klapper W, Dreyling M H, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29–38
- His E, Jung S-H, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma (MCL) treated with high dose therapy, stem cell transplantation, and rituximab: a Cancer and Leukemia B (CALGB) 59909 correlative science study
- Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750–762
- Rosenwald A, Wright G, Wiestner A, Chan W C, Connors J M, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197
- Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol, in press
- Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans H C, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565